Navigating the Efficacy-Tolerability Trade-Off – Linking Half-Life, Dosing & Clinical Outcomes to Define Amylin’s Competitive Advantage

This workshop tackles the fundamental question of where amylin therapeutics fit in the treatment landscape relative to GLP-1s. Participants will examine clinical readouts comparing amylin analogs to incretins, analyzing whether improved tolerability profiles allow higher dosing and greater efficacy. The session will explore the relationship between half-life and both efficacy and tolerability, discussing whether longer-acting molecules provide smoother pharmacokinetics with reduced GI side effects. Critical focus will be placed on patient populations: Do non-responders to GLP-1s respond better to amylins? Can amylins serve as maintenance therapy post-GLP-1 weight loss? The workshop will integrate preclinical biology with clinical data to understand how molecular design translates to patient outcomes.

What attendees will gain:

Attendees will develop strategies for positioning amylin therapeutics in clinical development, understanding patient segmentation opportunities, and designing molecules that optimize the efficacy-tolerability balance.

Key questions to be addressed:

• Do patients who don’t respond to or can’t tolerate GLP-1s respond better to amylin based therapeutics?
• How does half-life influence the efficacy-tolerability trade-off, and what is the optimal pharmacokinetic profile?
• Can amylins deliver better quality weight loss (lean mass preservation, reduced weight rebound) compared to GLP-1s?
• What is the ideal patient segmentation strategy for amylin therapeutics (first-line, second-line, maintenance, specific populations)?
• How do we link in vitro receptor pharmacology and in vivo preclinical data to predict clinical tolerability and efficacy?